Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment

被引：0
|
作者：
Robbrecht, D. G. [1 ]
van Soest, R. J. [2 ]
Tannock, I. F. [3 ]
Oudard, S. [4 ]
Tombal, B. [5 ]
Eisenberger, M. [6 ]
Mercier, F. [7 ]
de Wit, R. [1 ]
机构：
[1] Erasmus MC Daniel den Hoed Canc Ctr, Med Oncol, Rotterdam, Netherlands
[2] Erasmus MC Daniel den Hoed Canc Ctr, Urol, Rotterdam, Netherlands
[3] Princess Margaret Hosp, Med Oncol, Toronto, ON, Canada
[4] Hop European George Pompidou, Immunotherapie & Traitement Antiangiogen Pathol C, Paris, France
[5] Clin Univ St Luc, Urol, Brussels, Belgium
[6] Johns Hopkins Sidney Kimmel Canc Ctr, Med Oncol, Baltimore, MD USA
[7] Sanofi, Stat Proc, Charlotte, NC USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
813P
引用
收藏
相关论文
共 50 条
  • [1] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [2] Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Gamat-Huber, Melissa
    Jeon, Donghwan
    Johnson, Laura E.
    Moseman, Jena E.
    Muralidhar, Anusha
    Potluri, Hemanth K.
    Rastogi, Ichwaku
    Wargowski, Ellen
    Zahm, Christopher D.
    McNeel, Douglas G.
    CANCERS, 2020, 12 (10) : 1 - 23
  • [3] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [4] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Bilusic, Marijo
    Karzai, Fatima
    Cordes, Lisa M.
    Strauss, Julius
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Avelumab in metastatic castration-resistant prostate cancer (mCRPC).
    Fakhrejahani, Farhad
    Madan, Ravi Amrit
    Dahut, William L.
    Karzai, Fatima
    Cordes, Lisa M.
    Schlom, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [7] Monitoring of treatment for metastatic castration-resistant prostate cancer
    Hinz, Stefan
    AKTUELLE UROLOGIE, 2017, 48 (03) : 225 - 229
  • [8] Docetaxel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution
    Schallier, D.
    Decoster, L.
    Braeckman, J.
    Fontaine, C.
    Degreve, J.
    ANTICANCER RESEARCH, 2012, 32 (02) : 633 - 641
  • [9] Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
    Qureshi, Zaheer
    Fatima, Eeshal
    Safi, Adnan
    Khanzada, Mikail
    Altaf, Faryal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (04): : 206 - 214
  • [10] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
12345